iiinova — where your digital self keeps evolving

Reposted by Tom Newsom-Davis

Simon Kuestenmacher @simongerman600.bsky.social · 10/05/2025

There is healthy skepticism and there is this...

Tom Newsom-Davis @tnewsomdavis.bsky.social · 09/05/2025

Going through applications for BTOG Trainee Representatives in oncology and respiratory medicine The most extraordinary group of dynamic, motivated, committed individuals So impressive So hard to decide Every single one would be excellent

media.tenor.com

a man with a beard is standing in front of a microphone scratching his head

ALT: a man with a beard is standing in front of a microphone scratching his head

030

Reposted by Tom Newsom-Davis

Lung Cancer Research Foundation @lcrf.org · 16/04/2025

On our next livestreams: a look at how #LungCancer affects young people and women, with moderator Dr. Isabel Preeshagul. Wed, April 23: Young Lung Cancer w/ Dr. Eric Singhi @lungoncdoc.bsky.social, LCRF.org/together2 Wed, May 14: Women & Lung Cancer w/ Dr. Narjust Florez, LCRF.org/together

073

Reposted by Tom Newsom-Davis

Florez Lab @florezlab.bsky.social · 03/04/2025

Exciting news! @curetoday.bsky.social is hosting an incredible Young-Onset Lung Cancer Summit 🎉 Chaired by the amazing @lungoncdoc.bsky.social, this is a must-attend event for anyone looking to learn more about @younglungcancer.bsky.social!

122

Reposted by Tom Newsom-Davis

Igor Randulfe @randulfe.bsky.social · 22/04/2025

Happy to share our latest work, led by Dr Monaca. In a time-dependent analysis, we show that irAEs are associated with improved outcomes in ES-SCLC. Interestingly, neither high-grade irAEs nor the use of steroids appeared to negatively impact survival. www.sciencedirect.com/science/arti...

021

Tom Newsom-Davis @tnewsomdavis.bsky.social · 22/04/2025

Not only does ‘Repositories of Agriculture’ debase scientific publications through unsolicited paper requests, but they then get aggressive when you don’t reply. Extraordinary Think they need to review their PR skills (and conscience)

020

Reposted by Tom Newsom-Davis

Itai Yanai @itaiyanai.bsky.social · 16/04/2025

When the conference organizers ask if you can send in your slides a week in advance

420229

Tom Newsom-Davis @tnewsomdavis.bsky.social · 10/04/2025

❗️FLAURA2 approved by NICE❗️ Already on BlueTeq! Now an option for 1L EGFR+ pts Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen

063

Tom Newsom-Davis @tnewsomdavis.bsky.social · 09/04/2025

❗️BTOG / NLCA ‘State of the Nation’ webinar on 15th May❗️ The National Lung Cancer Audit has been instrumental in improvement of lung cancer outcomes in UK Come and hear about our successes and challenges. Neal Navani always gives a beautifully clear and concise talk. 👍

063

Tom Newsom-Davis @tnewsomdavis.bsky.social · 06/04/2025

This is an excellent series of discussions. Informed and informative. Highly recommend it. @katherinesleeman.bsky.social especially good, as she is always.

140

Reposted by Tom Newsom-Davis

Sanjay Popat @drsanjaypopat.bsky.social · 05/04/2025

Very important dataset and a set forward to potential ambulatory delivery in the future.

031

Tom Newsom-Davis @tnewsomdavis.bsky.social · 04/04/2025

🧐 Are you a 🇬🇧 Healthcare Professional treating lung cancer? 🤔 Do you want to learn how clinical research runs, whilst advancing your career? 💥 Be an Associate PI of a trial! 🥳 eVOLVE-Lung02 (I am 🇬🇧 CI) accepted into NIHR Associate PI programme Details here 👇 www.nihr.ac.uk/career-devel...

nihr.ac.uk

073

Reposted by Tom Newsom-Davis

Simon Kuestenmacher @simongerman600.bsky.social · 30/03/2025

What!? Tiramisu is younger than my dad? Also the 1940s saw great additions to our cuisine. Weird how young ciabatta is! Fun chart shows several foods that were invented surprisingly recently. Source: buff.ly/nvQgUns

87813

Reposted by Tom Newsom-Davis

EGFR Positive Lung Cancer UK @egfrpositiveuk.bsky.social · 28/03/2025

New data from the LAURA trial shared at #ELCC25 today shows promising results for Stage 3 unresectable EGFR+ #lungcancer. Giving osimertinib after chemoradiation meant people went much longer before needing further treatment — over 40 months, compared to just 9 months without it. #LCSM

052

Tom Newsom-Davis @tnewsomdavis.bsky.social · 28/03/2025

Predicting surgical complexity following neo-adjuvant chemoIO Single centre 🇬🇧 study 👉 43% defined as complex 🔺 Risk score includes x3 variables: ❇️ CN2 ❇️ Absence of nodal response ❇️ PD-L1 >50% #ELCC25

020

Tom Newsom-Davis @tnewsomdavis.bsky.social · 28/03/2025

LAURA OS update (LBA4) 👉 Now 31% maturity ❇️ 78% in PBO grp got Osi at PD ❇️ Improved PFS2 ❇️ Trend ⬆️ OS HR 0.67, not significant 💭 Confirm activity of Osi 💭 Crossover impacts OS difference 💭 Final maturity due @ 60% 💭 Surprised 1/3 Osi pts = no further treatment at PD #ELCC25

243

Reposted by Tom Newsom-Davis

Dr Colin Lindsay @drcolinlindsay.bsky.social · 27/03/2025

2) daraxonrasib (rmc-6236) offering early phase and v impressive activity in g12d g12v 2nd line nsclc. RR 38% and mPFS >10m. V tolerable toxicity profile again. Next will be IO combos, congrats+++ to Revolution Medicines and the investigators. #ELCC25

043

Reposted by Tom Newsom-Davis

Dr Colin Lindsay @drcolinlindsay.bsky.social · 27/03/2025

1) KRYSTAL-7 update on pembro+adagrasib in 1st line pdl1 >50% nsclc. Tox to navigate but mPFS >27m! Further reinforcing the view that ras orchestrates TME, not just cancer cell intrinsic pathways. Massive congrats to investigators, mirati, bms #ELCC25

065

Tom Newsom-Davis @tnewsomdavis.bsky.social · 27/03/2025

Great ROS1 TKI summary slide from Julian Mazieres

042

Tom Newsom-Davis @tnewsomdavis.bsky.social · 27/03/2025

COCOON: mitigating cutaneous toxicity of Amivantamab ✅ 60% reduction in Gr2+ dermatology AE ✅ Reduction scalp issues+ paronychia ✅ Fewer Ami dose amendments needed 💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy #ELCC25

033

Tom Newsom-Davis @tnewsomdavis.bsky.social · 27/03/2025

Case controlled indirect comparison of Taletrectinib v Crizotinib in ROS1 NSCLC 👉 From TRUST I + II / PROFILE 1091 trials ✅ ORR 90% v 71% ✅ Improved PFS, HR 0.48 👉 Similar Gr3 TRAEs 💭 Ph3 head-2-head ongoing 💭 In meanwhile, this suggests Taletrectinib superior 💭 Would like to see CNS data #ELCC25

141

Tom Newsom-Davis @tnewsomdavis.bsky.social · 27/03/2025

Tobemstomig (LAG3/PD1 bispecific) + chemo in 1L NSCLC 👉 Randomised Ph2 ❌ No ORR benefit ❌ No PFS benefit ❌ Higher Gr3+ TRAEs 💭 Not active combination 💭 Reality check on growing bispecific excitement 💭 Disappointing. LAG3 is hard to target. #ELCC25

042

Tom Newsom-Davis @tnewsomdavis.bsky.social · 27/03/2025

Pan-KRASi: RMC-6236 👉 NSCLC pts from Ph1 study ❇️ 200mg = Ph3 dose ❗️TRAE: mucocutaneous, GI, liver ❗️ Rash prophylaxis needed 👉 Clinical data from G12X popn: ❇️ ORR 38% ❇️ mPFS = 9.8m Ph3 RASolve-301 underway 💭 Need breakdown by mutant type 💭 Press release: safe combo w Pembro #ELCC25

021

Tom Newsom-Davis @tnewsomdavis.bsky.social · 26/03/2025

🇬🇧 healthcare has many challenges & shortcomings But we lead the world in lung cancer screening (many of these pioneers being on this paper) Now in routine clinical practice, causing stage shift. I see the effects every week. We need to bang the drum more about this 🥁

011

Tom Newsom-Davis @tnewsomdavis.bsky.social · 26/03/2025

ORCHARD (module 10): Osi + Dato-Dxd post 1L Osi ❇️ ORR 36 - 43% ❇️ mPFS 9.5 - 11.7m ❇️ DoR longer in 6mg/kg grp ❗️ 65% Dato dose reduction ❗️ 60% Dato dose interr 💭 Active combination 💭 Toxic+ 💭 Not biomarker directed #ELCC25

054

Tom Newsom-Davis @tnewsomdavis.bsky.social · 26/03/2025

BAY88 in HER2mut NSCLC Lower ORR, but similar DoR, if prior HER2 ADC (as opposed to treatment naive) #ELCC25

063

Tom Newsom-Davis @tnewsomdavis.bsky.social · 26/03/2025

SAVANNAH: Osi+Savolitinib in MET amp/OE EGFR+ post 1L Osi 👉 Protocol evolved over time 👉 34% pts have MET OE/amp ❇️ ORR 56%; mDOR 9.9m ❇️ mPFS 7.5m ❗️32% Gr3+ AE: oedema, N&V, diarr ❗️Dose amendments mainly for Savo 💭 Good that includes MET OE 💭 Expected side effects, not insignificant

012

Tom Newsom-Davis @tnewsomdavis.bsky.social · 26/03/2025

MARIPOSA final OS analysis ❇️ Significant HR 0.75 ❇️ 9% 3yr benefit ❇️ Projected mOS 4 years ❇️ Longer control of CNS disease ❗️At the cost of toxicity ❗️No data on duration of toxicity ❗️PROM and QoL data important More effective than Osimertinib Most suitable for higher risk pts #ELCC25

0117

Tom Newsom-Davis @tnewsomdavis.bsky.social · 26/03/2025

Love meetings in France: Madeleines & Petit four ❤️ Well done #ELCC25

020

Tom Newsom-Davis @tnewsomdavis.bsky.social · 26/03/2025

Racing through France Eurostar the best way to travel from 🇬🇧 to #ELCC25 🏎️

020

Tom Newsom-Davis @tnewsomdavis.bsky.social · 26/03/2025

Are you a respiratory or oncology trainee interested in lung cancer? Then apply to be part of the amazing @btog.bsky.social steering committee ⭐ Great experience ⭐ Great for your CV ⭐️ Great fun ⭐️ Great people ⭐ Great cause ❗️ Deadline 30.04.25

012

Reposted by Tom Newsom-Davis

BTOG @btog.bsky.social · 20/03/2025

Here's the highlights reel from our 2025 Annual Conference #BTOG25 It's also available to watch on the home page of our website at www.btog.org

043

Reposted by Tom Newsom-Davis

IASLC @iaslc.bsky.social · 20/03/2025

ICYMI: The US FDA grants zongertinib priority review for advanced HER2-positive NSCLC. 📰 Read the latest details in ILCN: bit.ly/3FvRaaR

bit.ly

US FDA Grants Priority Review for Zongertinib for Advanced HER2+ NSCLC - ILCN.org (ILCN/WCLC)

Data from the Beamion LUNG-1 trial show a 71% objective response rate in previously treated patients.

042

Reposted by Tom Newsom-Davis

BTOG @btog.bsky.social · 20/03/2025

BTOG is excited to call for Trainee Representatives from the Oncology and Respiratory specialities to apply to the BTOG Steering Committee. #LCSM Full details: www.btog.org/call-for-tra...

btog.org

Call for Trainee Representatives to Join BTOG Steering Committee | BTOG | British Thoracic Oncology Group

034

Reposted by Tom Newsom-Davis

EGFR Positive Lung Cancer UK @egfrpositiveuk.bsky.social · 20/03/2025

After Christine passed away in Oct 2024, her husband Sean met with her GP surgery to discuss her delayed EGFR+ #lungcancer diagnosis. Now, Banbury Cross Health Centre has made lung cancer in non-smokers part of their GP training. 💬 Patient advocacy changes conversations & outcomes. #LCSM

1123

Reposted by Tom Newsom-Davis

BTOG @btog.bsky.social · 19/03/2025

Congratulations to the winning posters from #BTOG25: Click to see the winners. www.btog.org/btog-2025-po...

011

Tom Newsom-Davis @tnewsomdavis.bsky.social · 13/03/2025

HER2 mutated NSCLC increasingly important as a rest of new TKI show promising effectiveness in early phase trials Riyaz Shah and I discuss these, and other HER2 targeted treatments

071

Reposted by Tom Newsom-Davis

BTOG @btog.bsky.social · 13/03/2025

New Podcast Alert! BTOG Does ... HER2. Featuring @tnewsomdavis.bsky.social, Dr Emma O'Dowd and Dr Riyaz Shah, listen wherever you get your podcasts (search 'BTOG') or online www.btog.org/btog-podcasts/ .

143

Reposted by Tom Newsom-Davis

UK Oncology Nursing Society @ukons.bsky.social · 11/03/2025

It's National Cancer CNS Day this Friday! 💙 🎥 The 2nd of our 3 special videos is out today! Watch the video about The Macmillan London CNS Development Pilot here: youtube.com/playlist?lis... Let’s make some noise for Cancer CNSs! 👏 #UKONS #NationalCancerCNSDay

youtube.com

National Cancer CNS Day 2025 - YouTube

Friday 14th March is #NationalCancerCNSDay. This is a day to celebrate and highlight the contribution of the specialist cancer nursing workforce. Start plann...

043

Reposted by Tom Newsom-Davis

EGFR Positive Lung Cancer UK @egfrpositiveuk.bsky.social · 11/03/2025

📊 40% of #lungcancer patients say they didn’t get enough details about their diagnosis.* 📊 22% of UK EGFR+ patients don’t know their mutation type—even though it affects treatment.** Patients can’t make informed choices without the right info. #LCSM * LuCE 9th Report ** EGFR+ UK member survey

092

Tom Newsom-Davis @tnewsomdavis.bsky.social · 06/03/2025

New chemotherapy unit & treatment centre at West Middlesex Hospital coming on nicely Chemo unit on top floor 😊 ETA 2026

130

Reposted by Tom Newsom-Davis

Yvonne Diaz @yvonnediaz.bsky.social · 05/03/2025

Professor @drjnaidoo.bsky.social welcomed to the #BTOG25 stage as a Lung Cancer Legend & doesn’t disappoint. Lots of discussion on how we turn discussions on Small Cell Lung Cancer on its head. Lots of optimism in #SCLC coming from new standards & future treatments. #LCSM

0187

Reposted by Tom Newsom-Davis

Gerry Hanna @gerryhanna.bsky.social · 05/03/2025

Well #BTOG25 that’s a wrap for 2025 from #Belfast Thanks to @btog.bsky.social for 3 fantastic years in Belfast It’s been an absolute pleasure to have the BTOG community over with us for the last 3 years 🙏 Here’s to next year in Edinburgh! @drsanjaypopat.bsky.social @tnewsomdavis.bsky.social

083

Reposted by Tom Newsom-Davis

BTOG @btog.bsky.social · 05/03/2025

The final session of #BTOG25 is ‘Non-medical Treatments in Cancer Patients’ chaired by Tom Newsom-Davis and Josie Roberts with 👉 Robert Thomas talking about vitamin D and sugar 👉 Chris Twelves talking about cannabinoids and cancer 👉 Robert Thomas talking about the evidence on gut health and cancer

031

Reposted by Tom Newsom-Davis

BTOG @btog.bsky.social · 05/03/2025

That’s it! As our 23rd annual conference closes, we’d like to thank our speakers for sharing their valuable expertise, our hosts in Belfast and all of our amazing attendees. See you again next year for #BTOG26 in Edinburgh! March 3-5 #BTOG25 #LCSM

161

Reposted by Tom Newsom-Davis

Jo Evans. @oncolojo.bsky.social · 05/03/2025

@drjnaidoo.bsky.social on the limited stage small cell space and the excitement around CCRT-Durvalumab. EAMS currently open in England… #BTOG25

0105

Reposted by Tom Newsom-Davis

Jo Evans. @oncolojo.bsky.social · 05/03/2025

@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25

0145

Reposted by Tom Newsom-Davis

Gerry Hanna @gerryhanna.bsky.social · 05/03/2025

Great session on systemic therapy for SCLC by @stephenvliu.bsky.social at #BTOG23 ➡️ BiTE engages, ADCs and many other agents showing promise ➡️ Possible role for radioligands ➡️ New never smokers phenotype emerging ➡️ Many reasons to be hopeful! @drjnaidoo.bsky.social @tnewsomdavis.bsky.social

073

Reposted by Tom Newsom-Davis

Gerry Hanna @gerryhanna.bsky.social · 05/03/2025

Although @stephenvliu.bsky.social is hard to follow, we’ve just had an absolute tour de force by @drjnaidoo.bsky.social at #BTOG25 on #SCLC ➡️ Discusses NRG005 and the better outcomes for patients reviving twice daily radiotherapy. ➡️ Continued evidence of a benefit from PCI in LS-SCLC

1145